Contact us to learn more about

our Premium Content: News alerts, weekly reports and conference planners

BIOMARKER:

FANCA mutation

Contact us to learn more about our Premium Content:

News alerts, weekly reports and conference planners

Entrez ID:

Related biomarkers:

‹

FANCA Q1307fs (1)

FANCA mutation + FGFR3 mutation (1)

FANCA Q1307fs (1)

FANCA mutation + FGFR3 mutation (1)

›

FANCA mutation	Prostate Cancer	FANCA mutation	Prostate Cancer	rucaparib Sensitive: C2 – Inclusion Criteria rucaparib Sensitive : C2	rucaparib Sensitive: C2 – Inclusion Criteria rucaparib Sensitive : C2
FANCA mutation	Prostate Cancer	FANCA mutation	Prostate Cancer	PARP inhibitor Sensitive: C3 – Early Trials PARP inhibitor Sensitive : C3	PARP inhibitor Sensitive: C3 – Early Trials PARP inhibitor Sensitive : C3
FANCA mutation	HER2 Negative Breast Cancer	FANCA mutation	HER2 Negative Breast Cancer	talazoparib Sensitive: C3 – Early Trials talazoparib Sensitive : C3	talazoparib Sensitive: C3 – Early Trials talazoparib Sensitive : C3
FANCA mutation	Colorectal Cancer	FANCA mutation	Colorectal Cancer	sintilimab + fruquintinib Resistant: C3 – Early Trials sintilimab + fruquintinib Resistant : C3	sintilimab + fruquintinib Resistant: C3 – Early Trials sintilimab + fruquintinib Resistant : C3
FANCA mutation	Prostate Cancer	FANCA mutation	Prostate Cancer	rucaparib + copanlisib Sensitive: C3 – Early Trials rucaparib + copanlisib Sensitive : C3	rucaparib + copanlisib Sensitive: C3 – Early Trials rucaparib + copanlisib Sensitive : C3
FANCA mutation	Ovarian Cancer	FANCA mutation	Ovarian Cancer	niraparib Sensitive: C4 – Case Studies niraparib Sensitive : C4	niraparib Sensitive: C4 – Case Studies niraparib Sensitive : C4